Docetaxel and 5-Fluorouracil for Metastatic Breast Cancer
Author Information
Author(s): Lortholary A, Delozier T, Monnier A, Bourgeois H, Bougnoux P, Tubiana-Mathieu N, Riffaud J Ch, Besson D, Lotz V, Gamelin E
Primary Institution: Centre Paul Papin, Angers, France
Hypothesis
The combination of docetaxel and 5-fluorouracil will improve treatment outcomes in patients with anthracycline-pretreated metastatic breast cancer.
Conclusion
The combination of docetaxel and 5-fluorouracil resulted in a 53.7% objective response rate in patients with metastatic breast cancer previously treated with anthracyclines.
Supporting Evidence
- The objective response rate was 53.7% in the intent-to-treat population.
- The median duration of response was 8.4 months.
- The median time to progression was 6.7 months.
- The combination was well tolerated with manageable toxicities.
Takeaway
Doctors tested a new medicine combination to help women with breast cancer that didn't get better with other treatments, and it worked for more than half of the patients.
Methodology
This was a phase II multicentre study involving 41 women with metastatic breast cancer who received docetaxel and 5-FU over several cycles.
Potential Biases
Potential selection bias due to the specific eligibility criteria for patient inclusion.
Limitations
The study had a small sample size and was limited to patients previously treated with anthracyclines.
Participant Demographics
Women aged 18–75 years with a median age of 53 years, previously treated with anthracycline-based chemotherapy.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI: 38.4–68.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website